Építés alatt – nem éles oldal

Ugrás a tartalomra

Frontlight Research

Vizsgálati helyszín

Institut Claudius Regaud

Toulouse, 31059, FranciaországMég nincs intézményhez kötve

33futó vizsgálat
30lezárt vizsgálat

Az itteni vizsgálatok

Miről szól a helyszín 65 vizsgálata, a regiszteri adatlapjaik szerint.

Betegségek: Petefészekrák18 vizsgálat
Tüdőrák12 vizsgálat
Áttétes emlőrák10 vizsgálat
Prosztatarák9 vizsgálat
Gyermekkori daganatok8 vizsgálat
Fej-nyaki daganatok7 vizsgálat
Melanóma6 vizsgálat
Szarkóma6 vizsgálat
Tripla negatív emlőrák6 vizsgálat
Hólyagrák5 vizsgálat
Méhnyakrák5 vizsgálat
Hasnyálmirigyrák4 vizsgálat
és még 15
Fázis: 3. fázis21 vizsgálat
2. fázis12 vizsgálat
1. fázis7 vizsgálat
1/2. fázis6 vizsgálat
2/3. fázis2 vizsgálat
Állapot: Lezárult25 vizsgálat
Fut, nem toboroz18 vizsgálat
Toboroz14 vizsgálat
Leállították3 vizsgálat
Felfüggesztve2 vizsgálat
Visszavonták2 vizsgálat
Még nem toboroz1 vizsgálat
Fő szponzor: UNICANCER12 vizsgálat
ARCAGY/ GINECO GROUP5 vizsgálat
Institut Claudius Regaud5 vizsgálat
Hoffmann-La Roche4 vizsgálat
Centre Leon Berard3 vizsgálat
és még 30

Futó vizsgálatok

Toboroz
Routine Shallow-coverage Whole Genome Sequencing Testing of Liquid-based Cervical Smears for the Early Diagnosis of Ovarian Cancer
NCT07821879· Institut Claudius Regaud· Forrás
Contact: Giulio Ricotta, Dr
Toboroz
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT06172478· 2. fázis· Daiichi Sankyo· Forrás
Toboroz
TTFields General Routine Clinical Care in ndGBM Patients: a French Prospective Non-Interventional Study (TIGER France)
NCT06924099· NovoCure Ltd.· Forrás
Contact: inst INSTITUT CLAUDIUS REGAUD
Toboroz
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
NCT05696626· 3. fázis· LeonaBio· Forrás
Fut, nem toboroz
Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer
NCT05552001· 3. fázis· UNICANCER· Forrás
Fut, nem toboroz
A Study to Test How Well Different Doses of Obrixtamig (BI 764532) in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3
NCT05879978· 1. fázis· Boehringer Ingelheim· Forrás
Toboroz
A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study
NCT05862285· 3. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy
NCT05840211· 3. fázis· Gilead Sciences· Forrás
Fut, nem toboroz
A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma
NCT05625399· 3. fázis· Bristol-Myers Squibb· Forrás
Fut, nem toboroz
A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery
NCT05608291· 3. fázis· Regeneron Pharmaceuticals· Forrás
Toboroz
Blocking TNF to Potentiate the ICI-dependent Immune Awakening in Melanoma
NCT05867004· Institut Claudius Regaud· Forrás
Contact: Bruno SEGUI, Pr
Toboroz
ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)
NCT04916613· 3. fázis· UNICANCER· Forrás
Fut, nem toboroz
HDM201 and Pazopanib in Patients With P53 Wild-type Advanced/Metastatic Soft Tissue Sarcomas
NCT05180695· 1/2. fázis· Centre Leon Berard· Forrás
Fut, nem toboroz
177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer
NCT05204927· 3. fázis· Curium US LLC· Forrás
Toboroz
Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer
NCT05183984· 2. fázis· ARCAGY/ GINECO GROUP· Forrás
Toboroz
Study on the Efficacy of Treatment by Radiotherapy and Pembrolizumab in Newly Diagnosed Metastatic Head & Neck Cancers
NCT04747054· 3. fázis· UNICANCER· Forrás
Contact: Anouchka MODESTO, Dr (principal investigator)
Fut, nem toboroz
A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors
NCT04931342· 2. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations
NCT04603001· 1. fázis· Eli Lilly and Company· Forrás
Toboroz
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
NCT04585750· 1/2. fázis· PMV Pharmaceuticals, Inc· Forrás
Contact: Carlos-Alberto Gomez-Roca, MD
Fut, nem toboroz
Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer Patients
NCT03870919· UNICANCER· Forrás
Toboroz
Erectile Dysfunction in Good Prognosis Prostate Cancer : Comparison Between Brachytherapy and Stereotactic Body Radiotherapy
NCT03830788· Center Eugene Marquis· Forrás
Contact: Pierre Graff-Cailleaud, MD (principal investigator)
Fut, nem toboroz
ESTIMation of the ABiLity of Prophylactic Central Compartment Neck Dissection to Modify Outcomes in Low-risk Differentiated Thyroid Cancer
NCT03570021· 3. fázis· Gustave Roussy, Cancer Campus, Grand Paris· Forrás
Fut, nem toboroz
Clinical and Biological Activity of an Anti-PD-L1 (Atezolizumab) in Operable Localised Soft Tissue Sarcomas Patients to be Treated With Radiotherapy
NCT03474094· 2. fázis· Centre Leon Berard· Forrás
Fut, nem toboroz
Adjuvant Radiotherapy in Patients With Pathological High-risk Bladder Cancer (GETUG-AFU 30)
NCT03333356· UNICANCER· Forrás
Fut, nem toboroz
PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer
NCT03774732· 3. fázis· UNICANCER· Forrás
Fut, nem toboroz
Stereotactic Body Radiotherapy for the Treatment of OPD
NCT03256981· 2/3. fázis· Institute of Cancer Research, United Kingdom· Forrás
Toboroz
Evolution of the Therapeutic Care in Lung Cancer in France Since 2015 (ESME LC)
NCT03848052· UNICANCER· Forrás
Contact: Delphine BERCHERY
Fut, nem toboroz
National Clinical-biological Prospective Cohort of Incident Cases of Aggressive Fibromatosis (ALTITUDES)
NCT02867033· Centre Oscar Lambret· Forrás
Fut, nem toboroz
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
NCT02568267· 2. fázis· Hoffmann-La Roche· Forrás
Toboroz
Evolution of the Therapeutic Care in Metastatic Breast Cancer From 2008
NCT03275311· UNICANCER· Forrás
Contact: Delphine BERCHERY
Fut, nem toboroz
A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer
NCT01957436· 3. fázis· UNICANCER· Forrás
Fut, nem toboroz
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
NCT01874353· 3. fázis· AstraZeneca· Forrás
Toboroz
French Childhood Cancer Survivor Study
NCT01620372· Institut National de la Santé Et de la Recherche Médicale, France· Forrás
Contact: Florent F. de Vathaire, Ph.D

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

Lezárt vizsgálatok

Visszavonták
Evaluation of the Stereotactic MR-guided Adaptive Radiotherapy for Locally Advanced Pancreatic Cancers
NCT07097064· 2. fázis· Institut du Cancer de Montpellier - Val d'Aurelle· Forrás
Toboroz
Superiority Trial Evaluating Digitalized Information Media for Patients With Advanced Sarcomas Receiving Systemic Treatment.
NCT06211257· Centre Oscar Lambret· Forrás
Contact: PANNIER Diane, DR
Lezárult
A Study to Evaluate Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants with Relapsed or Refractory Multiple Myeloma
2023-503689-21-00· 1/2. fázis· F. Hoffmann-La Roche AG· Forrás
Lezárult
Randomized, non-comparative, open-label early phase Ib study with OBT076 or OBT076 followed by Balstilimab in patients with Adenoid Cystic Carninoma of the Head and Neck
2023-503270-20-00· 1. fázis· Groupe Oncologie Radiotherapie Tete Cou· Forrás
Lezárult
Detection of tumor DNA in the blood of patients receiving standard therapy for hormone receptorpositive (HR+) non-HER2 expressing (HER2-) metastatic breast cancer as a tool to select those who may benefit from the next course of fulvestrant in combination with alpelisib or ribociclib.
2022-502372-22-01· 2. fázis· Unicancer· Forrás
Lezárult
Phase 1 First-In-Human Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors
NCT05800964· 1. fázis· Amgen Inc.· Forrás
Lezárult
Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome
NCT05673057· 1. fázis· Molecular Partners AG· Forrás
Toboroz
Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
2022-501876-24-00· 1. fázis· F. Hoffmann-La Roche AG· Forrás
Leállították
GEN1047 for Solid Tumors - First in Human (FIH) Trial
NCT05180474· 1/2. fázis· Genmab· Forrás
Lezárult
Multiomic Approach to Radioresistance of Ependymomas in Children and Adolescents
NCT05151718· Institut Claudius Regaud· Forrás
Lezárult
Olaparib Plus Pembrolizumab Compared to Chemotherapy Plus Pembrolizumab After Initial Treatment With Chemotherapy Plus Pembrolizumab in Triple-Negative Breast Cancer
2022-500418-24-00· 2/3. fázis· Merck Sharp & Dohme LLC· Forrás
Lezárult
Study of DF1001 in Patients With Advanced Solid Tumors
NCT04143711· 1/2. fázis· Dragonfly Therapeutics· Forrás
Lezárult
Study of DS-8201a, an Antibody Drug Conjugate for Advanced Breast Cancer Patients, With Biomarkers Analysis
NCT04132960· 2. fázis· UNICANCER· Forrás
Lezárult
Phase 3 Study of Pembrolizumab plus Enzalutamide in mCRPC
NCT03834493· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Leállították
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
NCT04234113· 1. fázis· SOTIO Biotech AG· Forrás
Leállították
Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)
NCT03869190· 1/2. fázis· Hoffmann-La Roche· Forrás
Lezárult
Phase II Study of Regorafenib as Maintenance Therapy
NCT03793361· 2. fázis· Centre Oscar Lambret· Forrás
Lezárult
Atezolizumab and Bevacizumab in Patients With Recurrent or Metastatic Squamous-cell Carcinoma of the Head and Neck
NCT03818061· 2. fázis· Centre Leon Berard· Forrás
Lezárult
UTOLA: UTerin OLAparib
NCT03745950· 2. fázis· ARCAGY/ GINECO GROUP· Forrás
Lezárult
Retarded Surgery Following Neoadjuvant Chemotherapy in Advanced Ovarian Cancer
NCT03579394· ARCAGY/ GINECO GROUP· Forrás
Lezárult
Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix
NCT03556839· 3. fázis· Grupo Español de Investigación en Cáncer de Ovario· Forrás
Lezárult
PEMBRO With Chemo in Neo Adj Treatment of Ovarian Cancer .
NCT03275506· 2. fázis· ARCAGY/ GINECO GROUP· Forrás
Lezárult
Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)
NCT03036488· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Lezárult
Cost Utility of Radical Surgery in Ovarian Cancer
NCT02854215· Institut Claudius Regaud· Forrás
Lezárult
Role of Geriatric Intervention in Treatment of Older Patients With Cancer (PREPARE)
NCT02704832· Institut Bergonié· Forrás
Lezárult
ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab
NCT02891824· 3. fázis· ARCAGY/ GINECO GROUP· Forrás
Lezárult
A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma
NCT02451943· 3. fázis· Eli Lilly and Company· Forrás
Lezárult
Comparison of Biological Features Between pN0 Triple Negative Breast Tumours With Size < or = 10 mm (pT1a/b) Versus pT1c T2 < or = 30 mm
NCT02266420· Institut Claudius Regaud· Forrás
Lezárult
Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer
NCT02003924· 3. fázis· Pfizer· Forrás
Lezárult
Letrozole in Preventing Breast Cancer in Postmenopausal Women With a BRCA1 or BRCA2 Mutation
NCT00673335· 3. fázis· UNICANCER· Forrás

Helyszínadatok: ClinicalTrials.govFrissítve: 2026. nov. 14.

Építés alatt, nem éles – Institut Claudius Regaud: vizsgálati helyszín – Frontlight Research